Thank you to our speakers, sponsors, and delegates who joined us in Boston for the summit!
If you are interested in the 2025 event, please get in touch at

Supercharge Antigen-Specific Immune Tolerance Strategies to Combat
& Cure Autoimmune Diseases

Welcome to the Antigen-Specific Immune Tolerance Drug Development Summit

Advance Durable Therapeutics Into Proof-of-Concept Trials & Beyond

The 7th Antigen-Specific Immune Tolerance Drug Development Summit returned as the definitive, industry-dedicated forum bringing you the latest discoveries, preclinical, proof-of-concept, biomarker, and clinical development on tolerogenic therapies.  

Immune tolerance approaches have unprecedented potential to not only treat autoimmune diseases but to cure them; resetting the immune system is the most advantageous approach in biopharma’s arsenal to trailblaze past standard immunosuppression treatments and create a new era of transformative therapies.  

With Diamyd’s phase III trial for type I diabetes, COUR, Anokion, Imcyse, Takeda, and Selecta’s phase II trials all underway, the field is on the precipice of advancing efficacious antigen-specific approaches for patients in need.  

What you missed:

Antigen-Summit Logo

Delve into antigen-selection and the role of T- and B- cells and tackle complex heterogeneous diseases including rheumatoid arthritis, multiple sclerosis, and more 

Antigen-Summit Logo

Evaluate biomarkers of tolerance and T- cell assays for preclinical and practical biomarkers for larger phase 2-3 clinical studies 

Antigen-Summit Logo

Explore the breadth of novel technologies, including CAR-Tregs, mRNA-LNPs, and more, to navigate dosage and frequency of administration and much more...

110+ autoimmune and immunologist scientists, corporate strategists, and large pharma scouts joined together at this timely and comprehensive summit set to unite the immune tolerance field. From innovative, start-up biotechs to big pharma super giants, this was your unique opportunity to discuss advancing efficacious antigen- and drug-specific tolerance approaches to patients in need

The 2024 World-Class Speaker Faculty Included:

Previously Attending Companies Include:

Abbvie Logo

Hear What Our Past Attendees Have Said:

“Highly interactive pre-conference workshops. The conference agenda was excellent and there were ample opportunities to discuss and network with the other attendees. One of my favourite conference experiences” GlaxoSmithKline